Treatment or new breakthrough in gastrointestinal mesothelioma (GIST), EMA grants Ilixadencel "orphan drug qualification"

Gastrointestinal mesothelioma (GIST) is a cancerous (malignant) tumor that is originally caused by a specific class of cells (interstitial precancer cells) in the esophageal, stomach, or intestinal wall.
most gastrointestinal mesotheliomas are caused by mutations in a cell growth control gene called C-KIT.
most of these tumors (60 to 70 percent) occur in the stomach, 20 to 25 percent in the small intestine, and a few in the esoesois, colon, and rectum.
age of diagnosis is 50 to 60 years.
these tumors usually grow slowly, but some grow faster and spread to other areas.
pharmaceutical company Immunicum AB recently announced that the European Medicines Agency (EMA) Orphan Drug Products Commission (COMP) awarded the company's candidate drug ilixadencel "orphan drug qualification" for the treatment of gastrointestinal mesothelioma (GIST).
COMP approval is based on the results of the GIST I/II clinical trial.
Ilixadencel is a cell-based cancer immunotherapy used to treat solid tumors.
its active ingredient is an allogeneic tree protrusion cell derived from the activated of healthy blood donors.
. Sven Rohmann, M.D., chief executive of Immunicum, said, "Both the EMA and the FDA have awarded imaxadencel orphan drug eligibility for GIST adaptation, which is an important step for Immunicum."